The last decade has seen an increase in the incidence and severity of Clostridium difficile infections (CDI), making it one of the most talked about disease topics with many recent congresses focusing on the disease.
As the leading cause of nosocomial diarrhoea in industrialised countries1 detection and treatment of CDI is extremely important. The ESCMID guidelines recommend that diagnosis is based upon both signs and symptoms and laboratory evidence of toxin producing C. difficile in stools.1,2 In addition antibiotic treatment to eradicate severe C. difficle infection is recommended in these guidelines.2
The management of systemic fungal infections is also a major challenge for healthcare professionals. Due to the invasive nature of fungal infections, many treatments are pre-emptive and are therefore initiated without identifying the specific fungus involved. Targeted approaches will become a more viable option as the speed and delivery of diagnostic methods improve.
The Anti-infectives Knowledge Centre aims to provide you with the most recent information in the areas of both CDI and systemic fungal infections with regularly updated content to help assist in the fight against these diseases.
The Knowledge Centre currently provides information on CDI, including:
- Prevalence – the incidence of CDI and the factors that have been attributed to the rise in these infections
- Symptoms – the symptoms of CDI, including how pseudomembranous colitis manifests
- Recurrence – the impact of recurring infection on patient outcomes
- Diagnosis – the importance of early diagnosis and the diagnostic tests available
- Treatment – treatment options recommended by the current ESCMID guidelines
Additional information on systemic fungal infections will be added soon.
Enter the Anti-infectives Knowledge Centre
1. Crobach MJ, et al. Clin Microbiol Infect 2009; 15: 1053‐1066
2. Bauer MP, et al. Clin Microbiol Infect 2009; 15: 1067‐1079
Date of preparation November 2012 AI/12/0038/EUc